Showing results (171-180 of 192) with videos related to
Sort By:
Pageof 20
Gynecologic Oncology|August 5, 2020
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatmentJung-Min Lee, Christina M Annunziata, John L Hays, et al.Cancer Research Communications|September 29, 2023
Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with CancerTheodore M Brasky, Alison M Newton, Sara Conroy, et al.Cancer Research|November 15, 2012
Definition of molecular determinants of prostate cancer cell bone extravasationSteven R Barthel, Danielle L Hays, Erika M Yazawa, et al.MMWR. Morbidity and Mortality Weekly Report|April 24, 2020
Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 - National Poison Data System, United States, January 1, 2020-March 31, 2020Arthur Chang, Amy H Schnall, Royal Law, et al.Future Oncology (London, England)|August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancerDavid M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.Journal of the National Cancer Institute|May 21, 2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJung-Min Lee, John L Hays, Christina M Annunziata, et al.Genetics|December 5, 2000
Extragenic suppressors of the nimX2(cdc2) mutation of Aspergillus nidulans affect nuclear division, septation and conidiationS L McGuire, D L Roe, B W Carter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerF A Holmes, J A O'Shaughnessy, S Vukelja, et al.Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2002
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyM D Green, H Koelbl, J Baselga, et al.Pageof 20